VANDETANIB |
GNF-PF-2188 |
ZD-64 |
ZD-6474 |
ZACTIMA |
CAPRELSA |
CH 331 |
N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYL-4-PIPERIDINYL)METHOXY)-4-QUINAZOLINAMINE |
CAPRELSA® |
N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE |
ZD6474 |
ZD 6474 |
4-(4-BROMO-2-FLUOROANILINO)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLINE |
chemidplus:443913-73-3 |
rxcui:1098413 |
pubchem.compound:3081361 |
drugbank:05294 |
chembl:CHEMBL24828 |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | antineoplastic agent |
FDA Approval | Medullary thyroid cancer |
Drug Class | Kinase Inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | drugs causing inadvertant photosensitivity |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | kinase inhibitor |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | oct2 inhibitors |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | photosensitizing agents |
Drug Categories | qtc prolonging agents |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Ephrin receptor inhibitor |
inhibitor (inhibitory) |
Trial Name | Zactima |
Novel drug target | Established target |
Direct Interaction? | True |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase BRK inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | Zactima |
Novel drug target | Established target |
combination therapy | Vandetanib + Temozolomide |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase TIE-2 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | Zactima |
Novel drug target | Established target |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
inhibitor (inhibitory) |
Notes | |
Trial Name | Zactima |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Ephrin receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
n/a |
Evidence Type | Actionable |
Approval Status | Phase II |
Response Type | no benefit |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase SRC inhibitor |
Direct Interaction | yes |
n/a |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
VANDETANIB | DrugBank Drug Name |
443913-73-3 | CAS Number |
Caprelsa | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | antineoplastic agents |
AZD6474 | Development Name |
VANDETANIB | Generic Name |
ZACTIMA | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Medullary thyroid cancer |
Drug Indications | antineoplastic agent |
Drug Class | small molecule |
FDA Approval | not approved |
VANDETANIB | Primary Drug Name |
VANDETANIB | Drug Generic Name |
CAPRELSA | Drug Trade Name |
CHEMBL24828 | ChEMBL Drug ID |
VANDETANIB | GuideToPharmacology Ligand Name |
D0G6QF | TTD Drug ID |